The Improvement of Black Raspberry in Obese and Mild AZ Patients Infected With H. Pylori

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05680532

Acronym

Enrollment

Registered

2023-01-11

Start date

2021-11-11

Completion date

2022-08-04

Last updated

2023-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, H Pylori Infection

Keywords

black raspberry, Alzheimer's patients, H pylori, Inflammatory cytokines, Antioxidant

Brief summary

The current study was designed to check the impact of black raspberry (BR) on obese and mild Alzheimers (AZ) patients infected with Helicobacter pylori (H pylori). Through checking various parameters including anthropometric, antioxidants, and CDR.

Detailed description

The current study was designed to check the impact of black raspberry (BR) on obese and mild Alzheimers (AZ) patients infected with Helicobacter pylori (H pylori). Preclinical studies (In vitro model) were conducted using 3T3-L1 adipocyte cells to check the anti-adhesion activity of BR. For the clinical trial, a total of 21 obese mild AZ patients were recruited and separated into 2 groups: Experimental (BR group) and Placebo group. Experimental group and Placebo group subjects were requested to take either 50 g of BR or 50 g of dextrin respectively for 4 weeks.

Interventions

DIETARY_SUPPLEMENTBlack raspberry

Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.

OTHERPlacebo

Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* BMI ≧ 27, Waist circumference: men ≧ 90cm, women ≧ 80cm, * Body fat: male ≧ 25%, female ≧ 30%, * UBT 13C test value\> 10‰ (H. pylori (+)), * CDR (clinical dementia rating) = 0.5

Exclusion criteria

* BMI\< 27 * Severe chronic diseases (liver disease, cardiovascular disease, kidney disease) * Alcohol abuse * Smoking habit * Taking berry-related supplementation or any known allergies related to berries. * Subjects with prior history of H. pylori infection were treated with triple therapy.

Design outcomes

Primary

Measure	Time frame	Description
Glycemic indices	8 weeks	No significant changes in any of the glycemic indices
Anthropometric parameters	8 weeks	BMI were significantly altered

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026